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1. INTRODUCTION {#dom13857-sec-0001}
===============

Diabetes is associated with accelerated risk of atherosclerosis. Diabetic dyslipidaemia is characterized by elevated triglyceride (TG) and low high‐density lipoprotein cholesterol (HDL‐C) levels, as well as qualitative and kinetic changes in lipoproteins that result in an atherogenic lipid profile.[1](#dom13857-bib-0001){ref-type="ref"}, [2](#dom13857-bib-0002){ref-type="ref"}, [3](#dom13857-bib-0003){ref-type="ref"}, [4](#dom13857-bib-0004){ref-type="ref"} Furthermore, diabetes itself appears to confer an independent risk factor for coronary heart disease (CHD), as at any given level of serum cholesterol, CHD risk is higher in patients with diabetes than in the general population.[3](#dom13857-bib-0003){ref-type="ref"}

Short‐acting glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), such as exenatide and lixisenatide, have been shown to improve postprandial proatherogenic lipids and vascular endothelial function, as well as exert antihyperglycaemic activity.[5](#dom13857-bib-0005){ref-type="ref"}, [6](#dom13857-bib-0006){ref-type="ref"}, [7](#dom13857-bib-0007){ref-type="ref"}, [8](#dom13857-bib-0008){ref-type="ref"}, [9](#dom13857-bib-0009){ref-type="ref"} Furthermore, long‐term use of such GLP‐1 RAs is associated with favourable changes in the lipid profiles of patients with type 2 diabetes.[10](#dom13857-bib-0010){ref-type="ref"}

iGlarLixi is a titratable fixed‐ratio combination of insulin glargine U100 (iGlar) and lixisenatide available as a single‐injection pen for once‐daily use. In LixiLan‐L (clinical trial number NCT02058160; <http://clinicaltrials.gov>), a 30‐week trial in patients with type 2 diabetes previously uncontrolled on basal insulin with or without oral antidiabetic drugs (OADs), iGlarLixi showed superior reductions in HbA1c levels and a beneficial effect on body weight compared with iGlar alone.[11](#dom13857-bib-0011){ref-type="ref"} This post hoc analysis of the LixiLan‐L trial investigated whether iGlarLixi improved fasting lipid levels versus iGlar alone, and whether achievement of glycaemic targets impacted changes in lipid levels.

2. METHODS {#dom13857-sec-0002}
==========

2.1. Trial design {#dom13857-sec-0003}
-----------------

The full methodology of the LixiLan‐L trial has been previously described.[11](#dom13857-bib-0011){ref-type="ref"} In brief, LixiLan‐L was a randomized, 30‐week, open‐label, parallel‐group, multicentre trial designed to compare the efficacy and safety of iGlarLixi versus iGlar in patients previously uncontrolled on basal insulin with or without up to two OADs. During a 6‐week run‐in period, all OADs other than metformin were discontinued prior to randomization. Additional details are described in the supporting material ([Appendix S1](#dom13857-supitem-0001){ref-type="supplementary-material"}).

2.2. Post hoc analysis {#dom13857-sec-0004}
----------------------

This post hoc analysis assessed the median percentage change and mean absolute change from baseline to week 30 in fasting lipid values \[TG, low‐density lipoprotein cholesterol (LDL‐C), total cholesterol (TC) and HDL‐C\], lipid ratios (TC/HDL‐C and TG/HDL‐C, which have been previously associated with cardiovascular/microvascular complications[12](#dom13857-bib-0012){ref-type="ref"}, [13](#dom13857-bib-0013){ref-type="ref"}) and body weight (median percentage change only) in the overall safety population and in patient subgroups stratified by achievement of glycaemic targets at week 30. Subgroups included the following: 2‐hour postprandial glucose \[PPG; ≤10, \>10 mmoL/L (≤180, \>180 mg/dL)\], fasting plasma glucose \[FPG; ≤6.1, \>6.1 mmoL/L (≤110, \>110 mg/dL)\] and HbA1c \[≤7, \>7% (≤53, \>53 mmol/mol)\]. As TG values were not normally distributed, absolute changes in TG levels were assessed using median values.

2.3. Lipid measurements {#dom13857-sec-0005}
-----------------------

Lipid levels were measured with standardized, automated, high‐throughput enzymatic analyses in a central lab. Serum total cholesterol, triglycerides and HDL‐C were measured by colorimetric methods on a Roche (Indianapolis, Indiana) Cobas analyser after an overnight fast. LDL‐C was then calculated according to the Friedewald formula.

2.4. Statistical analysis {#dom13857-sec-0006}
-------------------------

Post hoc analyses were based on the safety population, defined as all randomized patients who received at least one dose of iGlarLixi or iGlar, regardless of the amount of treatment administered. Student\'s t‐test was used to compare the mean difference between iGlarLixi versus iGlar for the absolute change in lipid levels (LDL‐C, TC and HDL‐C) and absolute change in TC/HDL‐C ratio from baseline. The Mann--Whitney U test was used to compare the differences in median absolute change in TG, median absolute change in TG/HDL‐C, median percentage change in lipid levels, and median percentage change in body weight between treatment groups.

Analysis of covariance (ANCOVA) was performed to explore the impact of covariates on changes in lipid levels. Least squares (LS) mean differences in absolute change from baseline in lipid levels between iGlarLixi and iGlar were calculated and compared using ANCOVA, with treatment as a fixed effect and baseline lipid levels, lipid‐lowering drug use and weight change at week 30 as covariates (analysed together or individually). The between‐treatment comparison for TG was based on Tukey normalized rank transformation. All *P*‐values are reported as nominal *P*‐values without multiplicity adjustment.

3. RESULTS {#dom13857-sec-0007}
==========

3.1. Patient baseline characteristics {#dom13857-sec-0008}
-------------------------------------

Patient baseline demographics and clinical characteristics were well balanced between the iGlarLixi and iGlar groups, as reported previously[11](#dom13857-bib-0011){ref-type="ref"} ([Table S1](#dom13857-supitem-0001){ref-type="supplementary-material"}). Baseline fasting lipid levels and use of lipid‐lowering drugs were also well balanced between treatment groups (Table [1](#dom13857-tbl-0001){ref-type="table"} and Table [S1](#dom13857-supitem-0001){ref-type="supplementary-material"}); baseline fasting lipid levels were similar across patient subgroups stratified by achievement of glycaemic targets at study end (Table [1](#dom13857-tbl-0001){ref-type="table"}).

###### 

Mean baseline lipid values (mmol/l) by treatment group, overall and in patients stratified by achievement of glycaemic targets at study end (safety population)

+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| Total population                  | iGlarLixi                    | iGlar                          |               |               |
+:==================================+:=============================+:===============================+:==============+:==============+
| TG                                | 1.41 (1.03, 1.89)            | 1.40 (1.05, 2.01)              |               |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| LDL‐C                             | 2.63 ± 0.99                  | 2.58 ± 0.95                    |               |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| TC                                | 4.72 ± 1.19                  | 4.65 ± 1.14                    |               |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| HDL‐C                             | 1.33 ± 0.35                  | 1.29 ± 0.32                    |               |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| **Subgroups by glycaemic target** |                              |                                |               |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| **2‐hour PPG**                    | **≤10 mmoL/L (≤180 mg/dL)**  | **\>10 mmoL/L (\>180 mg/dL)**  |               |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| **iGlarLixi**                     | **iGlar**                    | **iGlarLixi**                  | **iGlar**     |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
|                                   | **(n = 191)**                | **(n = 58)**                   | **(n = 142)** | **(n = 284)** |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| TG                                | 1.44                         | 1.50                           | 1.34          | 1.38          |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| (1.10, 2.06)                      | (1.14, 2.12)                 | (0.93, 1.85)                   | (1.04, 1.92)  |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| LDL‐C                             | 2.71 ± 1.00                  | 2.44 ± 0.96                    | 2.48 ± 0.95   | 2.61 ± 0.96   |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| TC                                | 4.79 ± 1.18                  | 4.51 ± 1.10                    | 4.60 ± 1.21   | 4.66 ± 1.16   |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| HDL‐C                             | 1.32 ± 0.36                  | 1.27 ± 0.32                    | 1.35 ± 0.35   | 1.28 ± 0.31   |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| **FPG**                           | **≤6.1 mmoL/L (≤110 mg/dL)** | **\>6.1 mmoL/L (\>110 mg/dL)** |               |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| **iGlarLixi**                     | **iGlar**                    | **iGlarLixi**                  | **iGlar**     |               |
|                                   |                              |                                |               |               |
| **(n = 161)**                     | **(n = 172)**                | **(n = 202)**                  | **(n = 192)** |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| TG                                | 1.42                         | 1.40                           | 1.41          | 1.39          |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| (1.07, 2.00)                      | (1.07, 1.92)                 | (1.01, 1.84)                   | (1.00, 2.01)  |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| LDL‐C                             | 2.75 ± 0.99                  | 2.59 ± 0.96                    | 2.52 ± 0.99   | 2.56 ± 0.94   |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| TC                                | 4.85 ± 1.15                  | 4.64 ± 1.13                    | 4.62 ± 1.22   | 4.65 ± 1.14   |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| HDL‐C                             | 1.33 ± 0.37                  | 1.27 ± 0.31                    | 1.33 ± 0.34   | 1.30 ± 0.33   |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| **HbA1c**                         | **≤7% (≤53 mmol/Mol)**       | **\>7% (\>53 mmol/Mol)**       |               |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| **iGlarLixi**                     | **iGlar**                    | **iGlarLixi**                  | **iGlar**     |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| **(n = 221)**                     | **(n = 123)**                | **(n = 142)**                  | **(n = 241)** |               |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| TG                                | 1.42                         | 1.44                           | 1.40          | 1.36          |
|                                   |                              |                                |               |               |
|                                   | (1.07, 1.91)                 | (1.07, 2.05)                   | (0.91, 1.85)  | (1.02, 1.91)  |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| LDL‐C                             | 2.68 ± 0.99                  | 2.45 ± 0.94                    | 2.55 ± 1.00   | 2.64 ± 0.95   |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| TC                                | 4.76 ± 1.17                  | 4.48 ± 1.06                    | 4.66 ± 1.23   | 4.73 ± 1.17   |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+
| HDL‐C                             | 1.34 ± 0.36                  | 1.24 ± 0.29                    | 1.33 ± 0.34   | 1.31 ± 0.34   |
+-----------------------------------+------------------------------+--------------------------------+---------------+---------------+

Abbreviations: FPG, fasting plasma glucose; HDL‐C, high‐density lipoprotein cholesterol; iGlar, insulin glargine U100; iGlarLixi, insulin glargine and lixisenatide; LDL‐C, low‐density lipoprotein cholesterol; PPG, postprandial plasma glucose; Q1, lower quartile; Q3, upper quartile; SD, standard deviation; TC, total cholesterol; TG, triglycerides.

Data are mean ± SD, except for TG, which is shown as median (Q1, Q3).

Of 736 patients randomized, the numbers of patients with lipid values available at both baseline and week 30 were 651 (TC and HDL‐C), 646 (TG) and 620 (LDL‐C).

3.2. Lipid levels {#dom13857-sec-0009}
-----------------

### 3.2.1. Changes in lipid levels by treatment group {#dom13857-sec-0010}

After 30 weeks of treatment, the median percentage change in fasting TG levels from baseline was statistically different between iGlarLixi and iGlar (*P* = 0.035). While there was little change with iGlarLixi {0.3% \[lower quartile (Q1), upper quartile (Q3): −19.8, 24.2\]}, there was an increase of 6.5% (Q1, Q3: −15.8, 33.5) with iGlar (Figure [1](#dom13857-fig-0001){ref-type="fig"}A). Similarly, TC levels were unchanged from baseline with iGlarLixi \[0% (Q1, Q3: −7.3, 10.1)\], while an increase was observed with iGlar \[3.4% (Q1, Q3: −5.6, 12.0)\], showing a trend of more favourable TC levels with iGlarLixi (*P* = 0.059; Figure [1](#dom13857-fig-0001){ref-type="fig"}A). LDL‐C levels were nearly unchanged from baseline with iGlarLixi, while numerical increases were observed with iGlar (Figure [1](#dom13857-fig-0001){ref-type="fig"}A). For HDL‐C, a numerically greater reduction (median percentage change) was observed in patients on iGlarLixi versus iGlar (Figure [1](#dom13857-fig-0001){ref-type="fig"}A). In general, similar trends were observed for absolute changes in lipid ratios ([Figure S1A](#dom13857-supitem-0001){ref-type="supplementary-material"}) and absolute changes in lipid levels ([Table S2](#dom13857-supitem-0001){ref-type="supplementary-material"}).

![Median percentage change in fasting lipid levels from (A) baseline overall and (B--G) in patient subgroups stratified by achievement of glycaemic targets at week 30 (safety population). Percentage change = \[(week 30 -- Baseline)/baseline\] × 100; *P*‐value calculated by Mann--Whitney U test. FPG, fasting plasma glucose; HDL‐C, high‐density lipoprotein cholesterol; iGlar, insulin glargine U100; iGlarLixi, insulin glargine and lixisenatide; LDL‐C, low‐density lipoprotein cholesterol; PPG, postprandial plasma glucose; TC, total cholesterol; TG, triglycerides](DOM-21-2712-g001){#dom13857-fig-0001}

### 3.2.2. Improvement in lipid levels according to achievement of glycaemic targets {#dom13857-sec-0011}

Changes in fasting lipid levels varied depending on whether or not patients achieved glycaemic targets (Figure [1](#dom13857-fig-0001){ref-type="fig"}B--G and [Table S2](#dom13857-supitem-0001){ref-type="supplementary-material"}). In the subgroups of patients who had met glycaemic targets, there was an improvement from baseline in lipid levels as assessed by median percentage change (TG, LDL‐C and TC) with iGlarLixi but not with iGlar across all glycaemic targets \[PPG ≤10 mmoL/L (≤180 mg/dL)\], FPG ≤6.1 mmoL/L (≤110 mg/dL) and HbA1c ≤7% (≤53 mmol/mol) at week 30; Figure [1](#dom13857-fig-0001){ref-type="fig"}B,D,F\]. Similar trends were observed for mean (LDL‐C, TC) or median (TG) absolute changes from baseline in lipid levels ([Table S2](#dom13857-supitem-0001){ref-type="supplementary-material"}).

In patients meeting the FPG target \[≤6.1 mmoL/L (≤110 mg/dL)\] at week 30, median percentage changes from baseline in TG and TC were statistically different between iGlarLixi and iGlar, favouring iGlarLixi (Figure [1](#dom13857-fig-0001){ref-type="fig"}D); significant differences between iGlarLixi and iGlar were also observed for median percentage change from baseline in LDL‐C and TC in patients meeting the HbA1c target \[≤7% (≤53 mmol/mol); Figure [1](#dom13857-fig-0001){ref-type="fig"}F; absolute changes summarized in [Table S2](#dom13857-supitem-0001){ref-type="supplementary-material"}\]. By contrast, in subgroups of patients who did not meet glycaemic targets, no significant differences were observed between iGlarLixi and iGlar (Figure [1](#dom13857-fig-0001){ref-type="fig"}C,E,G; [Table S2](#dom13857-supitem-0001){ref-type="supplementary-material"}). Although significant differences were not consistently observed between groups in absolute changes in lipid ratios, numeric trends generally favoured iGlarLixi ([Figure S1B--G](#dom13857-supitem-0001){ref-type="supplementary-material"}).

After accounting for baseline lipid values, lipid‐lowering drugs and weight change during the study, iGlarLixi showed a trend towards more favourable changes in absolute levels of TG, LDL‐C and TC compared with iGlar alone overall, based on LS mean differences in change from baseline between iGlarLixi and iGlar ([Figure S2A](#dom13857-supitem-0001){ref-type="supplementary-material"}). For TC and LDL‐C, these trends were observed in subgroups meeting glycaemic targets across all three glycaemic variables ([Figure S2B,D,F](#dom13857-supitem-0001){ref-type="supplementary-material"}). In patients achieving the PPG target, statistically significant differences were observed for LDL‐C after adjusting for all three covariates together or individually (*P* \< 0.05 for all, [Figure S2B](#dom13857-supitem-0001){ref-type="supplementary-material"}). For TG, more favourable outcomes with iGlarLixi versus iGlar overall and in patients meeting the FPG target were significant when adjusting for baseline TG value (*P* \< 0.05) or antilipid therapy (*P* \< 0.05), but not when adjusting for weight change alone ([Figure S2A,D](#dom13857-supitem-0001){ref-type="supplementary-material"}).

### 3.2.3. Body weight {#dom13857-sec-0012}

Overall, patients generally experienced no weight gain or some weight loss with iGlarLixi regardless of whether glycaemic targets were met ([Figure S3](#dom13857-supitem-0001){ref-type="supplementary-material"}). However, changes in weight were more favourable for patients who achieved glycaemic targets (PPG, FPG and HbA1c) with iGlarLixi. By contrast, patients tended to experience some weight gain with iGlar, regardless of whether glycaemic targets were met ([Figure S3](#dom13857-supitem-0001){ref-type="supplementary-material"}).

### 3.2.4. iGlar doses {#dom13857-sec-0013}

Mean iGlar doses at baseline and week 30 were similar between treatment groups and in patient subgroups stratified by achievement of glycaemic targets ([Table S3](#dom13857-supitem-0001){ref-type="supplementary-material"}).

4. DISCUSSION {#dom13857-sec-0014}
=============

This post hoc analysis of the LixiLan‐L trial showed that fixed‐ratio combination therapy with iGlarLixi was associated with more favourable lipid profiles compared with iGlar alone after 30 weeks of treatment in patients with type 2 diabetes uncontrolled on basal insulin. Furthermore, in patients who achieved glycaemic control, iGlarLixi was associated with improvements from baseline in lipid profiles; these improvements were not observed in patients treated with iGlar alone.

The improvement in lipid profiles with iGlarLixi over iGlar is probably provided by the short‐acting GLP‐1 RA component lixisenatide, as prior studies have showed the beneficial effects of lixisenatide and exenatide on lipid variables.[5](#dom13857-bib-0005){ref-type="ref"}, [6](#dom13857-bib-0006){ref-type="ref"}, [8](#dom13857-bib-0008){ref-type="ref"} The improvements observed with iGlarLixi may be partly mediated by its efficacy in correcting hyperglycaemia rather than by a direct effect on lipid levels, as the effect was clearly evident in patients who met glycaemic targets. However, patients on iGlar who achieved glycaemic targets did not show improvement in lipid profiles, pointing to a possible alternative mechanism for the lipid‐lowering effects of iGlarLixi, independent of its glycaemic effects. In general, a trend towards improvements in lipids with iGlarLixi versus iGlar was observed when adjusting for antilipid therapy, weight change and baseline lipids, suggesting that improvements, at least in part, were independent of these factors. Of note, the beneficial effect of iGlarLixi on LDL‐C levels in patients reaching their PPG target remained significant versus iGlar after adjusting for these covariates.

In line with other glucose‐lowering agents including GLP‐1 RAs, an improvement of HDL‐C was not observed with iGlarLixi.[1](#dom13857-bib-0001){ref-type="ref"}, [14](#dom13857-bib-0014){ref-type="ref"}, [15](#dom13857-bib-0015){ref-type="ref"} However, it should be noted that it is possible for compositional changes in HDL to confer antiatherogenic effects.[14](#dom13857-bib-0014){ref-type="ref"}, [16](#dom13857-bib-0016){ref-type="ref"} As lipid subclasses were not measured in the current study, the effect of iGlarLixi on HDL‐C composition could not be determined.

One limitation of the study was that postprandial lipids were not measured; as short‐acting GLP‐1 RAs such as lixisenatide have previously been shown to improve lipid variables following meals,[5](#dom13857-bib-0005){ref-type="ref"}, [6](#dom13857-bib-0006){ref-type="ref"}, [8](#dom13857-bib-0008){ref-type="ref"} it is possible that the addition of postmeal assessments would have yielded different results. Numerous other variables (eg, inflammatory markers, enzymes involved in lipid synthesis or metabolism, size of lipoproteins) could have provided additional information on potential changes in cardiovascular risk but were not designated for collection in the study. Another limitation was the open‐label design, but this was required to account for differences in the administration of iGlarLixi and iGlar. The study was also of short duration (30 weeks); therefore, long‐term studies will be required to assess duration of responses. As this was a post hoc analysis, the sample size and power calculations performed for primary study endpoints may not have been optimal for this analysis. Real‐world studies may help elucidate the effects of iGlarLixi on lipid profiles in routine clinical practice.

In conclusion, in patients with type 2 diabetes uncontrolled on basal insulin, achieving glycaemic control was associated with an improvement in the fasting lipid profile with iGlarLixi versus iGlar. Improvement in lipid levels in patients achieving glycaemic targets may contribute to cardiovascular benefits.
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